"ovarian neoplasms"[MeSH Major Topic] - Search Results

Year	Number of Results
1945	28
1946	83
1947	90
1948	110
1949	109
1950	111
1951	197
1952	203
1953	219
1954	218
1955	239
1956	198
1957	241
1958	226
1959	213
1960	247
1961	294
1962	292
1963	439
1964	558
1965	332
1966	288
1967	296
1968	283
1969	305
1970	266
1971	313
1972	298
1973	253
1974	267
1975	298
1976	318
1977	347
1978	368
1979	461
1980	389
1981	505
1982	554
1983	592
1984	677
1985	754
1986	702
1987	772
1988	818
1989	990
1990	998
1991	886
1992	1054
1993	1184
1994	1151
1995	1109
1996	1164
1997	1219
1998	1207
1999	1266
2000	1364
2001	1396
2002	1423
2003	1652
2004	1731
2005	1886
2006	2083
2007	2154
2008	2190
2009	2366
2010	2420
2011	2675
2012	2856
2013	2887
2014	3152
2015	3261
2016	3292
2017	3049
2018	3036
2019	3368
2020	3674
2021	3619
2022	3618
2023	3470
2024	935

1

Stromal cartilage oligomeric matrix protein as a tumorigenic driver in ovarian cancer via Notch3 signaling and epithelial-to-mesenchymal transition.

Gorji-Bahri G, Krishna BM, Hagerling C, Orimo A, Jirström K, Papadakos KS, Blom AM. Gorji-Bahri G, et al. J Transl Med. 2024 Apr 13;22(1):351. doi: 10.1186/s12967-024-05083-0. J Transl Med. 2024. PMID: 38615020 Free PMC article.

2

Comprehensive analysis of the interaction of antigen presentation during anti-tumour immunity and establishment of AIDPS systems in ovarian cancer.

Sun W, Xu P, Gao K, Lian W, Sun X. Sun W, et al. J Cell Mol Med. 2024 Apr;28(8):e18309. doi: 10.1111/jcmm.18309. J Cell Mol Med. 2024. PMID: 38613345 Free PMC article.

3

Application of interpretable machine learning algorithms to predict distant metastasis in ovarian clear cell carcinoma.

Guo QH, Xie FC, Zhong FM, Wen W, Zhang XR, Yu XJ, Wang XL, Huang B, Li LP, Wang XZ. Guo QH, et al. Cancer Med. 2024 Apr;13(7):e7161. doi: 10.1002/cam4.7161. Cancer Med. 2024. PMID: 38613173 Free PMC article.

4

The Clinicopathological Significance of the Cyclin D1/E1-Cyclin-Dependent Kinase (CDK2/4/6)-Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers.

Lashen A, Algethami M, Alqahtani S, Shoqafi A, Sheha A, Jeyapalan JN, Mongan NP, Rakha EA, Madhusudan S. Lashen A, et al. Int J Mol Sci. 2024 Apr 5;25(7):4060. doi: 10.3390/ijms25074060. Int J Mol Sci. 2024. PMID: 38612869 Free PMC article.

5

A Stem-like Patient-Derived Ovarian Cancer Model of Platinum Resistance Reveals Dissociation of Stemness and Resistance.

Suzuki T, Conant A, Jung Y, Bax R, Antonissen A, Chen W, Yu G, Ioffe YJ, Wang C, Unternaehrer JJ. Suzuki T, et al. Int J Mol Sci. 2024 Mar 29;25(7):3843. doi: 10.3390/ijms25073843. Int J Mol Sci. 2024. PMID: 38612653 Free PMC article.

6

MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian Cancer.

Flores-Colón M, Rivera-Serrano M, Reyes-Burgos VG, Rolón JG, Pérez-Santiago J, Marcos-Martínez MJ, Valiyeva F, Vivas-Mejía PE. Flores-Colón M, et al. Int J Mol Sci. 2024 Mar 28;25(7):3793. doi: 10.3390/ijms25073793. Int J Mol Sci. 2024. PMID: 38612604 Free PMC article.

7

Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.

Kong D, Wu Y, Liu Q, Huang C, Wang T, Huang Z, Gao Y, Li Y, Guo H. Kong D, et al. Eur J Med Res. 2024 Apr 12;29(1):231. doi: 10.1186/s40001-024-01814-7. Eur J Med Res. 2024. PMID: 38609993 Free PMC article.

8

Common misconceptions and myths about ovarian cancer causation: a national cross-sectional study from palestine.

Elshami M, Jaber I, Alser M, Al-Slaibi I, Jabr H, Ubaiat S, Tuffaha A, Khader S, Khraishi R, Arafeh ZA, Al-Madhoun S, Alqattaa A, Yaseen A, El Hadi AA, Barhoush O, Hijazy M, Eleyan T, Alser A, Hziema AA, Shatat A, Almakhtoob F, Mohamad B, Farhat W, Abuamra Y, Mousa H, Adawi R, Musallam A, Albarqi SI, Abu-El-Noor N, Bottcher B. Elshami M, et al. BMC Public Health. 2024 Apr 12;24(1):1027. doi: 10.1186/s12889-024-18437-6. BMC Public Health. 2024. PMID: 38609950 Free PMC article.

9

Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.

Tran TM, Chand Thakuri BK, Nurmukhambetova S, Lee JJ, Hu P, Tran NQ, Steimle B, Dash P, Schneider D. Tran TM, et al. J Immunother Cancer. 2024 Apr 12;12(4):e008261. doi: 10.1136/jitc-2023-008261. J Immunother Cancer. 2024. PMID: 38609317 Free article.

10

Spotlight on New Hallmarks of Drug-Resistance towards Personalized Care for Epithelial Ovarian Cancer.

Frezzini S, Lonardi S. Frezzini S, et al. Cells. 2024 Mar 31;13(7):611. doi: 10.3390/cells13070611. Cells. 2024. PMID: 38607050 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

83,723 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

83,723 results

Results by year